<DOC>
	<DOCNO>NCT00794157</DOCNO>
	<brief_summary>This study design provide pivotal confirmation efficacy safety data 2 dos indacaterol ( 150 300 µg daily [ od ] ) patient moderate severe chronic obstructive pulmonary disease ( COPD ) . Data study use registration indacaterol Japan .</brief_summary>
	<brief_title>Confirmatory Study Indacaterol Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Diagnosis moderatetosevere chronic obstructive pulmonary disease ( COPD ) , classify Global Initiative Chronic Obstructive Lung Disease ( GOLD ) guideline : 1 . Smoking history least 20 packyears . 2 . Postbronchodilator force expiratory volume 1 second ( FEV1 ) &lt; 80 % ≥ 30 % predict normal value . 3 . Postbronchodilator FEV1/FVC ( force vital capacity ) &lt; 70 % . Patients hospitalize COPD exacerbation 6 week prior screen 14 day runin period prior randomization . Patients require longterm oxygen therapy ( &gt; 15 hour day ) chronic hypoxemia . Patients respiratory tract infection within 6 week prior screen . Patients concomitant pulmonary disease . Patients history asthma . Patients diabetes Type I uncontrolled diabetes Type II . Any patient lung cancer history lung cancer . Any patient active cancer history cancer le 5 year diseasefree survival time . Patients history long QT syndrome whose QTc interval ( Bazett 's ) measure screen randomization prolong . Patients vaccinate live attenuate vaccine within 30 day prior screen runin period . Patients unable successfully use dry powder inhaler device perform spirometry measurement . Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>COPD</keyword>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>indacaterol</keyword>
	<keyword>long act β2-agonist</keyword>
</DOC>